Shares of Cassava Sciences (NASDAQ:SAVA) -- the biotech company responsible for Alzheimer's drug candidate simufilam -- are up 15% as of Thursday's market close after the company released interim data from a study funded by the National Institutes of Health.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,